Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

P21 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is P21 administered in research settings?

In research settings, P21 is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs P21

Peptide Comparison

Davunetide vs P21

Q: What is the difference between Davunetide and P21?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. P21: Derived from CNTF; increases BDNF expression and promotes hippocampal neurogenesis; modulates PI3K/Akt pathway

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

P21

CNTF fragment

CognitiveNot EvaluatedResearch Only

Half-life: Unknown

4 providers listed

Full P21 profile →

Bottom line

Davunetide carries stronger published evidence (RCT, 3 key studies) than P21 (Animal, 2); both are research compounds.

Quick Verdict

Davunetide

Evidence

Clinical

P21

Evidence

Preclinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Davunetide
Further along in FDA review	Davunetide
More provider options (0 vs 4)	P21

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

P21

Mechanism Family

Neuro & Cognitive

Half-life

—

Unknown

FDA Status

investigational

not evaluated

Admin Routes

intranasal, subcutaneous

subcutaneous, intranasal

Availability

Research Only

Providers

None listed

4 listed

Avail. Notes

—

CNTF-derived pentapeptide fragment studied for cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Very limited human research. Research compound.

Research Evidence

Davunetide

ClinicalRCT · 3 key studies · most recent 2026

P21

PreclinicalAnimal · 2 key studies · most recent 2017

Research Citations

Davunetide

Cohort2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

P21

Animal2017 · Journal of Alzheimer's Disease

Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Tre…

Animal2010 · FEBS Letters

Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic…

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About P21

Derived from CNTF; increases BDNF expression and promotes hippocampal neurogenesis; modulates PI3K/Akt pathway

Research Areas

neurogenesisBDNF upregulationmemory enhancementneuroprotection

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

P21

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

P21

4 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.